ODOVIE SAFETY DATA SHEET

Section 1. Identification of the substance/mixture and of the company/undertaking

1.1 Product Identifier

Product Name: Depakene syrup

Synonyms: Depakene Oral Solution; Depakene Jarabe; Valcote JBE; Depakine JBE; Valproic

Acid Oral Solution

List Number: 5682

1.2 Relevant identified uses of the substance or mixture and uses advised against

Recommended use: Pharmaceuticals

1.3 Details of the supplier of the safety data sheet

Supplier: AbbVie Inc.

1 North Waukegan Road North Chicago, IL 60064

USA

+1-847-932-7900

Customer Service Telephone: 1-800-255-5162 (US and Canada only)

+1-847-937-7433

E-mail Address: AbbVie.SDS@abbvie.com

1.4 Emergency telephone number

Emergency Telephone: CHEMTREC: 1(800) 424-9300 (in USA and Canada)

or +1-703-527-3887 (international)

Section 2. Hazards identification

2.1 Classification of the substance or mixture

Regulation (EC) No 1272/2008

Reproductive toxicity Category 1A

Classification according to EU Directives 67/548/EEC or 1999/45/EC
Risk Phrases:
R61 - May cause harm to the unborn child

2.2 Label elements



Signal Word: Danger

Hazard Statements: H360 - May damage fertility or the unborn child

Precautionary Statements P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/container to an approved waste disposal plant

2.3 Other hazards

Not determined

Section 3. Composition/information on ingredients

Chemical Name	Percent	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH No.
Sucrose 57-50-1	40-60	Present		Not Hazardous*	No data available
Water 7732-18-5	20-40	Present		Not Hazardous*	No data available
Sorbitol 50-70-4	5-20	Present		Not Hazardous*	No data available
Glycerol 56-81-5	5-20	Present		Not Hazardous*	No data available
Valproic Acid 99-66-1	1-10	Present	Xn, R22; Xi, R36/38; R61	Acute Tox Oral 4 (H302) Skin Irrit. 2 (H315) Eye Irrit. 2 (H319) Repro Cat1A (H360)	No data available

Not Hazardous* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

For the full text of the R-phrases mentioned in this Section, see Section 16

For the full text of the H-Statements mentioned in this Section, see Section 16

Section 4. First aid measures

4.1 Description of first aid measures

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Naloxone has been reported to reverse the CNS depressant effects of valproic acid. Provide

symptomatic/supportive care, monitoring liver function as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Naloxone has been reported to reverse the CNS depressant effects of valproic acid. Provide

symptomatic/supportive care, monitoring liver function as necessary.

Inhalation: Remove from source of exposure. If signs of irritation or toxicity occur seek

medical attention. Naloxone has been reported to reverse the CNS depressant effects of valproic acid. Provide symptomatic/supportive care, monitoring liver

function as necessary.

Ingestion: Remove from source of exposure. If irritation persists or signs of toxicity occur,

seek medical attention. Naloxone has been reported to reverse the CNS depressant effects of valproic acid. Provide symptomatic/supportive care, monitoring liver

function as necessary.

Protection of First-aiders: Use personal protective equipment

4.2 Most important symptoms and effects, both acute and delayed

Signs and Symptoms: No signs and symptoms from occupational exposure are known. Direct contact

with the eyes could result in the following: eye irritation. Clinical data suggests the following: headaches, nausea, lack of energy, dizziness, gastrointestinal upset, muscle weakness, leucopenia, anemia, thrombocytopenia, vomiting, abdominal pain, anorexia, abnormal liver function. Clinical overdose may result in the

following: coma.

Medical Conditions Aggravated by Exposure: No medical conditions aggravated by occupational exposure are known. Data suggest any pre-existing ailments in the following organs: eyes, skin, pancreas, liver. Hypersensitivity to the material and/or similar materials. liver, nervous system, male reproductive system, female reproductive system,

gastrointestinal system, or hematopoietic system.

4.3 Indication of any immediate medical attention and special treatment needed

Notes To Physician: Treat symptomatically

Section 5. Firefighting measures

5.1 Extinguishing Media

Suitable Extinguishing Media: Use extinguishing agent suitable for type of surrounding fire

Unsuitable Extinguishing Media: Not determined

5.2 Special hazards arising from the substance or mixture

Special Exposure Hazards: Not determined

5.3 Advice for firefighters

Protective Equipment and Precautions for Firefighters:

As in any fire, wear self-contained breathing apparatus and full protective gear

Section 6. Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal Precautions: For personal protection see section 8.

6.2. Environmental precautions

Environmental Precautions: Contain material and prevent release to waterways or soil.

6.3. Methods and material for containment and cleaning up

Methods for Cleaning Up: Recover product and place in an appropriate container for disposal.

6.4. Reference to other sections

Refer to Sections 8, 12, and 13 for further information.

Section 7. Handling and storage

7.1. Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Store according to label instructions.

7.3. Specific end use(s)

Recommended use: Pharmaceuticals

Section 8. Exposure controls/personal protection

8.1. Control parameters

Exposure limits:

Chemical Name	Employee Exposure Limit	Skin Notation
Sucrose 57-50-1	Not Applicable	None
Water 7732-18-5	Not Applicable	None
Sorbitol 50-70-4	Not Applicable	None
Glycerol 56-81-5	Not Applicable	None
Valproic Acid 99-66-1	160 mcg/m ³	None

Chemical Name	ACGIH TLV	France	German MAK	Ireland	Italy
Sucrose 57-50-1	10 mg/m³ TWA	TWA: 10 mg/m ³		20 mg/m ³ (STEL) 10 mg/m ³ (TWA)	
Glycerol 56-81-5	10 mg/m³ (total mist)	TWA: 10 mg/m ³	100 mg/m ³ Peak	10 mg/m ³ (TWA)	

Chemical Name	The Netherlands	Spain	Switzerland	UK OEL/MEL
Sucrose 57-50-1		10 mg/m ³ (TWA)		20 mg/m³ (STEL)
Glycerol		10 mg/m³ (TWA)	50 mg/m³ (TWA)	10 mg/m ³ (TWA) 30 mg/m ³ (STEL)
56-81-5		(1 1111)	100 mg/m³ (STEL)	10 mg/m³ (TWA)

8.2. Exposure controls

Engineering Controls: No special provisions are required under normal product use conditions.

When handling bulk formulation, use in a well-ventilated area.

Respiratory Protection: Respiratory protection is not needed during normal product use. When handling

the bulk formulation, an approved respirator (i.e. NIOSH, EN, etc.) should be

worn when exposures are expected to exceed the applicable limits.

Eyes: Eye protection not needed during typical product use conditions. Wear eye

protection as appropriate when handling the bulk formulation.

Gloves: Gloves not required during normal product use conditions. Wear impervious

gloves when handling the bulk formulation.

Other PPE Data: Wear appropriate body coverings if contact may occur.

Environmental Exposure

Controls:

Not determined

Section 9. Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance: Red Liquid
Odor: Cherry odor
Odor Threshold: Not determined

pH: 7-8

Boiling Pt. @ **760** mm **Hg** (°C): Not determined. **Melting/Freezing Point (°C):** Not determined Flash Point (°C): Not determined. **Evaporation Rate at 20°C:** Not determined. Flammability (Solid): Not determined. **Lower Explosive Limit:** Not determined. **Upper Explosive Limit:** Not determined. Vapor Pressure (mm Hg): Not determined. Vapor Density (Air = 1): Not determined. Density, g / mL: 1.28-1.31

Specific Gravity: Not determined.

Solubility(ies): Freely soluble in: water.

Partition coefficient: Not determined.

n-octanol/water

Autoignition Temp. (°C): Not determined. **Decomposition temperature** Not determined.

(°C):

Viscosity (centipoise):

Explosion Severity:

Oxidizer Properties:

Not determined.

Not determined.

9.2. Other information

Not determined

Section 10. Stability and reactivity

10.1. Reactivity

Not determined

10.2. Chemical stability

Stable under normal conditions

10.3. Possibility of hazardous reactions

Hazardous reactions: Not determined.

10.4. Conditions to avoid

Not determined.

10.5 Incompatible materials

Not determined

10.6 Hazardous decompostion products

Carbon oxides, Nitrogen oxides (NOx)

Section 11. Toxicological information

11.1. Information on toxicological effects

Routes of Exposure:

Oral: Clinical Route
Dermal: Not determined.
Inhalation: Not determined.

Acute Toxicity - Oral: Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Sucrose 57-50-1	LD50 >	29,700	mg/kg	Rats
Sorbitol 50-70-4	LD50 =	15900-17800	mg/kg	Mice
Glycerol 56-81-5	LD50 >	4090	mg/kg	Animals
Valproic Acid 99-66-1	LD50 =	670-2307	mg/kg	Rats Mice

Acute Toxicity - Dermal: Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Glycerol	LD50 >	10,000	mg/kg	Rabbits
56-81-5				

Acute Toxicity - Inhalation: Data for component (s) given below.

Chemical Name	Test	Value	Units	Species
1- 3	LC 50 >	0.57	mg/L , 1 hour	Rats
56-81-5				

Corrosivity: Not determined.

Dermal Irritation: Active Ingredient : Produced mild to moderate skin irritation in animals.

Eye Irritation: Active Ingredient: Produced severe eye irritation in animals. Recovery after 24

hours.

Sensitization: Not determined.

Toxicokinetics/Metabolism: Not determined.

Target Organ Effects: Not determined.

Reproductive Effects: Active Ingredient: In animals adverse reproductive effects include: testicular

atrophy, reduced sperm count, fetal abnormalities. fetal toxicity. In humans adverse reproductive effects include: fetal abnormalities.

Data for component (s) given below.

Chemical Name	Species	Dosage	Units	Route	Duration
Valproic Acid	Rats	> 65	mg/kg	Oral	During Gestation
99-66-1	Mice				_
	Rabbits				

Carcinogenicity: None expected from normal clinical use of this product. Confirmed animal

carcinogen with unknown relevance to humans

Data for component(s) given below.

Chemical Name	Site of Tumors	Species	Dosage	Route	Units	Duration
Valproic Acid	Liver Lungs	Rats	80-170	Oral	mg/kg	2 years
99-66-1						

Mutagenicity: Data for component (s) given below.

Chemical Name	Micronucleus Assay	Ames Test:	Mouse Lymphoma	Chromosomal Abbr.
			Assay	Assay
Glycerol	No Data.	Negative	No Data.	No Data.
56-81-5				

Aspiration hazard: Not determined

Notes:

1. ALD: Approximate lethal dosage

2. LC50: Concentration in air that produces 50% mortality

3. LD50: Oral or dermal dosage that produces 50% mortality

Section 12. Ecological information

12.1. Toxicity

Not determined.

12.2. Persistence and degradability

Not determined.

12.3. Bioaccumulative potential

Not determined

12.4. Mobility in soil

Not determined.

12.5. Results of PBT or vPvB assessment

Chemical safety report is not required for this substance/product.

12.6. Other adverse effects

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

Notes:

- 1. EC50: Concentration in water that produces 50% mortality in Daphnia sp.
- 2. LC50: Concentration in water that produces 50% mortality in fish.
- 3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

Section 13. Disposal considerations

13.1 Waste treatment methods

Waste Disposal Methods: Disposal should be made in accordance with country, federal, state and local

regulations.

Section 14. Transport information

ADR, DOT, ICAO/IATA, IMDG/IMO

Status: Not regulated

14.1. UN Number: Not applicable
14.2. Proper shipping name: Not applicable
14.3. Hazard class: Not applicable
14.4. Packing group: Not applicable
14.5. Environmental hazard: Not applicable
14.6. Special Provisions: Not applicable
14.7. Transport in bulk

according to Annex II of MARPOL 73/78 and the IBC

Code:

Section 15. Regulatory Information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Sucrose 57-50-1	Present	X	X	Not listed.	X
Water 7732-18-5	Present	X	X	Not listed.	X
Sorbitol 50-70-4	Present	X	X	Not listed.	X
Glycerol 56-81-5	Present	X	X	Not listed.	X
Valproic Acid 99-66-1	Present	-	X	Not listed.	X

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Sucrose 57-50-1	-	Present	-	X	Present	
Water 7732-18-5	-	2-(4)-1220	-	X	Present	
Sorbitol 50-70-4	Present	-	-	X	Present	
Glycerol 56-81-5	Present	-	-	X	Present	
Valproic Acid 99-66-1	Present	Present	-	X	Present	HSR006827

Legend

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

PICCS - Philippines Inventory of Chemicals and Chemical Substances

ENCS - Japan Existing and New Chemical Substances

ISHL - Japan Industrial Safety and Health Law

IECSC - China Inventory of Existing Chemical Substances

AICS - Australian Inventory of Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

Carcinogenicity Rating:

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Sucrose	40-60	Not Listed	Not Listed	Not Listed
Water	20-40	Not Listed	Not Listed	Not Listed
Sorbitol	5-20	Not Listed	Not Listed	Not Listed
Glycerol	5-20	Not Listed	Not Listed	Not Listed
Valproic Acid	1-10	Not Listed	Not Listed	Not Listed

SARA 313 Information

Chemical Name	Percent	SARA 313 Chemical:	CERCLA RQ/SARA	SARA EHS TPQ
			EHS RQ (lbs):	(lbs):
Sucrose	40-60	No	Not Applicable	Not applicable
Water	20-40	No	Not Applicable	Not applicable
Sorbitol	5-20	No	Not Applicable	Not applicable
Glycerol	5-20	No	Not Applicable	Not applicable
Valproic Acid	1-10	No	Not Applicable	Not applicable

Immediate Health:NoDelayed Health:NoFire:NoSudden Pressure:NoReactivity:No

RCRA Status: Not determined.

Proposition 65 Status: Listed. Reproductive toxicity

Component	Percent	Proposition 65 Listed Materials
Valproic Acid	1-10	developmental toxicity, initial date 7/1/87
99-66-1 (1-10)		

WHMIS Hazard Class: Not determined.

NFPA Rating:

Health: 0 Fire: 1 Reactivity: 0

Notes:

- $1.\ SARA = Superfund\ Amendments\ and\ the\ Reauthorization\ Act.$
- 2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
- 3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
- 4. TSCA = Toxic Substances Control Act.
- 5. EC = European Community.
- 6. WHMIS = Canadian Workplace Hazardous Materials Information System.
- 7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

15.2. Chemical safety assessment

Chemical safety assessment has not been conducted on the substance/product.

Section 16. Other information

Risk Phrases:

R61 - May cause harm to the unborn child

Full text of H-Statements referred to under sections 2 and 3

H360 - May damage fertility or the unborn child if inhaled

Document Authored By: Occupational and Environmental Toxicology

Issued: Jul-02-2015

Supersedes the SDS dated: Sep-03-2011

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.